A moat isn't a vibe — it's a testable claim that a business can defend its profits from competition. Using Intuitive Surgical as a case study, this post walks through the four moat sources you can actually verify (switching costs, an installed-base flywheel, regulatory barriers, and accumulated know-how), the numbers that prove a moat is real, and the uncomfortable truth that widening a moat sometimes costs near-term revenue.
- •"It has a moat" is a claim, not a conclusion. Like any thesis claim, it should be falsifiable: name the mechanism, then name the evidence that would prove it — or disprove it.
- •The strongest moats compound: Intuitive's installed base of surgical systems generates recurring instrument revenue, trained surgeons, and procedure data that each make the next hospital's decision easier.
- •Moat evidence lives in numbers, not narratives — pricing power, gross margins that hold under attack, retention of the installed base, and recurring revenue as a share of the total.
- •Real moats sometimes get wider by getting less profitable in the short run. Intuitive extending the usable life of its instruments cuts near-term revenue per procedure but deepens customer lock-in.
- •Every moat erodes eventually. The honest investor pre-registers the erosion signals — share losses, discounting, margin compression — the same way they pre-register any other thesis break.
What Makes a Real Moat? Intuitive Surgical as a Case Study
Everyone says they invest in companies with moats. Few can say what would prove the moat exists — or that it's eroding. A walkthrough using Intuitive Surgical, the robotic-surgery company, as a live example.
"Wide moat" might be the most overused phrase in investing. Everyone wants to own businesses with moats. Almost nobody, when pressed, can say precisely what their company's moat is, what evidence proves it exists, or what would tell them it's eroding.
That's a problem, because a moat is not a feeling. It's a claim — a claim that this business can defend its profits from competitors for years. And like any investment claim, it should be falsifiable. In our last post we argued that a thesis is a set of statements you can prove wrong; a moat is simply one of those statements, and usually the most important one.
So let's do this properly, with a live example: Intuitive Surgical (ISRG), the company behind the da Vinci robotic-surgery system. It's one of the most commonly cited moat businesses in the market — which makes it a perfect test case for separating the mechanism from the mythology.
Start with the mechanism, not the label
The classic moat taxonomy — switching costs, network effects, cost advantages, intangibles like brands and patents, regulatory barriers — is useful, but only as a starting point. The label is worthless without the mechanism. "ISRG has switching costs" explains nothing. Why would a customer who wants to leave find it painful to do so? That's the question.
For Intuitive, the mechanism looks like this:
The hospital's sunk investment. A da Vinci system is a seven-figure capital purchase, but the machine is the smallest part of the commitment. The hospital builds operating-room workflows around it, trains its surgical teams on it, and markets its robotic-surgery program to patients. Ripping that out to install a competitor's platform means re-doing all of it.
The surgeon's sunk investment. This is the deeper layer. Surgeons spend enormous time climbing the learning curve on a specific platform — and a surgeon's proficiency is measured in patient outcomes, not convenience. Asking an experienced da Vinci surgeon to start over on a rival system is asking them to be temporarily worse at their job, with real clinical stakes. Surgeons, understandably, resist. Hospitals, which compete to recruit surgeons, listen.
The installed-base flywheel. Intuitive has built its platform into more than 11,000 hospitals and surgical centers worldwide. Each installed system generates recurring revenue — the instruments and accessories consumed in every procedure, plus service contracts — which in practice makes up the large majority of the company's revenue. This is the razor-and-blades model at industrial scale: the system is the razor, every procedure buys blades. But the flywheel is more than financial. Every procedure also produces data, refines training programs, and adds to the pool of surgeons who know the platform — which makes the next hospital's purchasing decision easier. Scale feeds scale.
The regulatory and evidence barrier. Surgical robots need regulatory clearance procedure by procedure, market by market, and hospitals adopting them want published clinical evidence. Intuitive has a two-decade head start on both. A competitor doesn't just need a good robot; it needs years of approvals and outcome data before hospitals will trust it with patients.
Notice what this adds up to: four layers that reinforce each other. That's what separates a genuine moat from a single advantage. One barrier can be engineered around. Four interlocking ones are a different proposition.
Now demand the evidence
A mechanism is a hypothesis. The numbers are the test. If the moat above is real, it should show up in exactly the places a moat is supposed to protect:
Pricing power. A moated company sets prices; a commoditized one accepts them. Watch whether the company can hold or raise prices on its recurring revenue streams without losing customers. The early warning of erosion is discounting — deals won on price are deals a moat should have won on lock-in.
Gross margins under attack. Intuitive's gross margins have historically sat at levels most hardware companies can only dream of. The test isn't the level — it's the trajectory while competitors attack. A moat that only holds margins in the absence of competition was never tested.
Retention of the installed base. The single most direct measurement: do existing customers leave? Systems get replaced at end of life — are they replaced with the same platform or a rival's? A moat business should show near-total retention even when alternatives exist.
Recurring share of revenue. The higher the share of revenue that renews automatically through usage, the less the business depends on winning new deals in contested territory each quarter. For Intuitive, procedures — not system sales — are the engine, which is precisely why procedure growth is the number the market watches most closely.
Every one of these is checkable each quarter, from public filings. Which means "ISRG has a moat" can graduate from opinion to monitored claim.
The uncomfortable part: moats and profits can point in opposite directions
Here's the nuance that separates a real moat analysis from a promotional one.
In recent years, Intuitive has been extending the approved usable life of its instruments — letting hospitals get more procedures out of each one before replacement. Think about what that does. It directly reduces near-term revenue per procedure: fewer instruments sold for the same surgical volume. Analysts fret about it every quarter, and reasonably so.
But look at it through the moat lens and the picture inverts. Lowering the per-procedure cost for hospitals makes the platform harder to displace, strengthens the customer relationship, and raises the bar a competitor's economics have to clear. The company is trading revenue today for lock-in tomorrow.
That's not unusual — it's what genuinely moated companies do. Amazon spent two decades being accused of sacrificing profits; it was buying scale advantages. The lesson for an investor is that a moat-widening move can look like deterioration in the income statement. If you're monitoring the thesis rather than the headline, you need to decide in advance which is which: "revenue per procedure declines because the company is cutting customer costs" is a different claim, with different implications, than "revenue per procedure declines because competitors are undercutting us." Same line item. Opposite meanings.
No moat is permanent — pre-register the erosion signals
Intuitive spent most of two decades as effectively the only game in town. That era is ending. Medtronic's Hugo system and Johnson & Johnson's Ottava are real programs from companies with enormous resources, and other entrants are pushing in specific procedure niches and price-sensitive international markets.
This is not a reason to avoid the stock — every great business eventually attracts attack, and moats exist precisely to survive it. But it is the reason moat faith is dangerous. The honest approach is the same one we apply to any thesis: write down, in advance, what erosion would look like. Losing head-to-head placements at existing customers. Discounting to close deals. Gross margin compression that can't be explained by product mix or deliberate moat-widening moves. Procedure share shifting to rival platforms in the niches where competition is live.
None of those things individually kills the thesis. A pattern of them does. The investor who pre-registered the signals will see the pattern in the filings. The investor running on moat faith will see it in the stock price — years later, and much poorer.
The takeaway
A moat is the most valuable thing a business can own and the easiest thing for an investor to hallucinate. The discipline that separates the two is the same one that runs through everything we write here: name the mechanism, demand the numbers, pre-register what failure looks like, and check — on a schedule, from the filings, without flinching.
Because the market is full of stories about castles. The filings tell you whether the water in the moat is real.
New here? This post builds on how to monitor a stock you own and whether your portfolio is really diversified.